# Sovaldi® (sofosbuvir) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/sofosbuvir

> The FDA approved Sovaldi® (sofosbuvir), sponsored by GILEAD SCIENCES, INC. (GILD), on August 28, 2019.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Sovaldi® (sofosbuvir) |
| Codes |  |
| Sponsor | GILEAD SCIENCES, INC. (GILD) https://sec-api.dev/companies/gild/catalysts |
| Indications | [population and achieving the trial's primary endpoint](https://sec-api.dev/indications/population-and-achieving-the-trial-s-primary-endpoint) |
| Modality | small_molecule |
| FDA designations | priority review |

## Timeline

### August 28, 2019: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA212480 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20190828, review_priority PRIORITY; sponsor_name GILEAD SCIENCES INC; product SOVALDI (SOFOSBUVIR)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212480%22

### Jul 2026: topline data readout

- Status: completed, positive. Date confidence: month. Indication: population and achieving the trial's primary endpoint.
- First seen 2026-11-09, last confirmed 2026-11-09.
- SEC Form 10-Q (accession 0001193125-26-453807): "In July 2026, the Company announced positive topline results from C-BEYOND with BEM/RZR demonstrating statistical non-inferiority to the regimen of sofosbuvir and velpatasvir in the modified intent to treat population and achieving the trial's primary endpoint." https://www.sec.gov/Archives/edgar/data/1593899/000119312526453807/avir-20260930.htm

## Same indication

- [Bemnifosvbuvir](https://sec-api.dev/pdufa/bemnifosvbuvir) (AVIR)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/sofosbuvir.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Sovaldi® (sofosbuvir) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/sofosbuvir

```bibtex
@misc{secapidev_pdufa_sofosbuvir_20261116,
  title        = {Sovaldi® (sofosbuvir) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/sofosbuvir}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_sofosbuvir_20261116","title":"Sovaldi® (sofosbuvir) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/sofosbuvir","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
